Selective pharmacological JAK1 inhibition significantly reduces the expression of typical proinflammatory mediators such as CXCL chemokines, BLyS, TRAIL, and AIM2 in CLE in vitro models and also improves skin lesions in lupus-prone TREX1–/– -mice markedly. The gene discussed is TNFSF10; the disease is systemic lupus erythematosus.